-1753359733653.webp&w=3840&q=75)
2025 NOSCM | HER2 Positive Breast Cancer: Individualizing Treatment to Biology and Response
0% Complete
Course Overview
Dr. Mark Pegram discussed the DESTINY-Breast09 trial, showing superior PFS with tucatinib plus pertuzumab.
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Objectives
NA
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Mark Pegram, MD
Disclosure
<p>NA</p>
Accreditation
NA
Related Courses
-1773064384760.webp&w=3840&q=75)
2026 Winter Cancer Symposium | Optimal Therapy for Metastatic Triple Negative Breast Cancer
0.00 AMA PRA Category 1 Credits™
1 Chapter
Breast
Free
-1773063945796.webp&w=3840&q=75)
2026 Winter Cancer Symposium | New therapies for Metastatic Hormone Receptor Positive Breast Cancer: Sequencing SERDs, CDKi, PI3Ki and ADCs
0.00 AMA PRA Category 1 Credits™
1 Chapter
Breast
Free